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Edited by Veli-Pekka LehtoAbstract We have shown that exposure of the HER2/neu-over-
expressing breast cancer cells to apigenin resulted in induction of
apoptosis by depleting HER2/neu protein and, in turn, suppress-
ing the signaling of the HER2/HER3-PI3K/Akt pathway. Here,
we examined whether inhibition of this pathway played a role in
the anti-tumor eﬀect. The results revealed that treatment with
apigenin induced apoptosis through cytochrome c release and
caused a rapid induction of caspase-3 activity and stimulated
proteolytic cleavage of DFF-45. Furthermore, apigenin downreg-
ulated cyclin D1, D3 and Cdk4 and increased p27 protein levels.
Colony formation in the soft agar assay, a hallmark of the trans-
formation phenotype, was preferentially suppressed in HER2/
neu-overexpressing breast cancer cells in the presence of apige-
nin. In addition, a structure–activity relationship study indicated
that (1) the position of B ring; and (2) the existence of the 3 0, 4 0-
hydroxyl group on the 2-phenyl group were important for the
depletion of HER2/neu protein by ﬂavonoids. These results pro-
vided new insights into the structure–activity relationship of
ﬂavonoids.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Flavonoids1. Introduction
Flavonoids may be considered to be potential compounds
for selectively blocking signal transduction pathways. Based
on their skeleton, ﬂavonoids are classiﬁed into eight groups:
ﬂavans, ﬂavanones, isoﬂavanones, ﬂavones, isoﬂavones, anth-
ocyanidines, chalcones and ﬂavonolignans. Epidemiological
studies have shown that the consumption of vegetable, fruits
and tea is associated with a decreased risk of cancer and car-
diovascular diseases, and ﬂavonoids are believed to play an
important role in preventing these diseases [1]. Flavonoids in
human diet may reduce the risk of various cancers [2], espe-
cially hormone-dependent breast and prostate cancers, and
prevent menopausal symptoms. These data indicate that cer-*Corresponding author. Fax: +886 2 2391 8944.
E-mail address: jklin@ha.mc.ntu.edu.tw (J.-K. Lin).
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.11.061tain ﬂavonoids may be used as possible chemoprotective or
chemotherapeutic agents.
Breast cancer is the most frequently diagnosed malignancy
among women, with an approximate incidence of one million
new cases worldwide annually. Two genes with particular sig-
niﬁcance to this disease are erbB2 (HER2/neu) and cyclin D1.
Both genes have prognostic signiﬁcance because they are fre-
quently overexpressed and implicated in experimental models
of breast cancer [3,4]. The HER2/neu oncogene, the second
member of the epidermal growth factor (EGF) receptor family,
encodes a transmembrane receptor protein tyrosine kinase.
Overexpression of HER2/neu, which has been seen in approx-
imately 30% of breast cancers, is associated with poor overall
survival [5]. In particular, it has been found to be associated
with increased metastatic potential and resistance to chemo-
therapeutic agents. Interactions between HER2/neu and cyclin
D1 appear to have therapeutic relevance, because the anti-
HER2/neu monoclonal antibody trastuzumab (Herceptin) re-
duces cyclin D1 protein levels [6]. In addition, ﬂavopiridol
inhibits CDK activity, lowers cyclin D1 levels [7], and reduces
HER2/neu receptor levels [8]. Cyclin D1 functions were ﬁrst
shown to be downstream of HER2/neu-mediated transforma-
tion in tissue culture models. In murine models, cyclin D1-deﬁ-
cient mice were completely resistant to erbB2-mediated
mammary tumorigenesis [9]. The combination of these ﬁndings
in both mouse models and in human specimens would be a
stringent test for the idea that cyclin D1 is downstream of,
and required for, the HER2/neu-mediated tumorigenesis.
Apoptosis, a genetically regulated form of cell death, is one
of the important pathways through which chemotherapeutic
agents inhibit the growth of cancer cells [10]. It can be trig-
gered by various extracellular and intracellular stimuli that
result in coordinated activation of a family of cysteine prote-
ases called caspases. In response to certain apoptotic stimuli,
cytochrome c is released from mitochondria [11,12] into the
cytoplasm, where it has an entirely diﬀerent function. The re-
leased cytochrome c induces the formation of a caspase acti-
vation complex with Apaf-1, which directly binds the
zymogen form of caspase-9 via a homophilic interaction
involving CARD (the caspase recruitment domain) [13].
The CARD is a region of highly conserved residues in the
amino terminus of molecules that are recruited for complex
signaling during apoptosis. Activated caspase-9 can proteo-
lytically process the zymogen form of downstream caspases,
such as caspase-3 [14].blished by Elsevier B.V. All rights reserved.
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lavone) is a chemopreventive compound and an inhibitor of
certain signal transduction pathways [15]. We have shown that
apigenin induces apoptosis by depleting HER2/neu protein in
HER2/neu-overexpressing MDA-MB-453 breast cancer cells
via proteasomal degradation. Furthermore, the inhibition of
cell growth and induction of apoptosis by apigenin may be
through suppression of HER2/HER3 signaling and disruption
of the PI3K/Akt-dependent pathway [16]. In this study, we
examined whether the signaling-pathways downstream of
HER2/neu that regulate cell cycle progression and/or cell death
are modiﬁed by apigenin. Moreover, we investigated the inhib-
itory action of 19 ﬂavonoids of four chemical classes on the
degradation of HER2/neu protein, to identify the structural
requirements of ﬂavonoids necessary for modulating the po-
tency of the degradation of HER2/neu protein.2. Materials and methods
2.1. Chemicals
Flavone, 5-methoxyﬂavone, 7,8-dihydroxyﬂavone, apigenin,
kaempferol, quercetin, myricetin, rutin, and genistein were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Chrysin, luteolin,
galangin, ﬁsetin, pinocembrin, naringenin, isosakuranetin, eriodictyol,
hesperetin, and biochanin A were purchased from Extrasynthese Inc.
(Genay, France).
2.2. Cell culture
The human breast cancer cell lines used in this study were MDA-
MB-453, BT-474, and SKBr-3, all of which overexpress HER2/neu,
and MCF-7 and T47-D which express the basal level of HER2/neu.
We also used HBL-100 cell line, which is derived from a normal human
breast tissue transformed by SV40 large T antigen and expresses a ba-
sal level of HER2/neu. All of the cells were grown in DMEM/F12 (Life
Technologies) supplemented with 10% fetal bovine serum (Life Tech-
nologies) and gentamicin (50 mg/ml). Cells were grown in a humidiﬁed
incubator at 37 C under 5% CO2.
2.3. Caspase activity
After treatment, cells were collected and washed with PBS and resus-
pended in 25 mM HEPES (pH 7.5), 5 mM MgCl2, 5 mM EDTA, 5
mM dithiothreitol (DTT), 2 mM PMSF, 10 mg/ml pepstatin A and
10 mg/ml leupeptin. Cell lysates were clariﬁed by centrifugation at
12 000 rpm for 15 min and the clear lysates containing 150–500 lg
of protein were incubated with 2.5 mM substrate Ac-DEVD-AMC
at 30 C for 1 h. Levels of released 7-amino-4-methyl coumarin
(AMC) were measured using a spectroﬂuorometer (Hitachi F-4500)
with excitation at 360 nm and emission at 460nm (Promegas Ca-
spACE2 Assay System, Madison, WI, USA).
2.4. Cytochrome c release
Mitochondrial and cytosolic fractions were prepared by resuspend-
ing cells in ice-cold buﬀer A [250 mM sucrose, 20 mM HEPES, 10
mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, 17 mg/ml PMSF, 8 mg/ml aprotinin and 2 mg/ml leupeptin
(pH 7.4)). Cells were passed through a 27G-needle 10 times. Unlysed
cells and nuclei were pelleted by centrifugation for 10 min at 750 · g.
The supernatant was then centrifuged at 100 000 · g for 15 min. The
pellet was resuspended in buﬀer A and represents the mitochondrial
fraction. The supernatant was centrifuged again at 100 000 · g for 1
h. The ﬁnal supernatant represents the cytosolic fraction.
2.5. Western blot analysis
Cells (1.5 · 106) were seeded onto a 100-mm tissue culture dish con-
taining 10% FBS DMEM/F12 and cultured for 24 h. Then, cells were
incubated in 1% FBS DMEM/F12 treating with various dosees of api-
genin for various time periods. Cells were washed three times with PBS
and then lysed in gold lysis buﬀer (10% glycerol, 1% Triton X-100, 137mM NaCl, 10 mM NaF, 1 mM EGTA, 5 mM EDTA, 1 mM sodium
pyrophosphate, 20 mM Tris–HCl, pH 7.9, 100 mM b-glycerophos-
phate, 1 mM sodium orthovanadate, 0.1% sodium dodecyl sulfate,
10 lg/ml aprotinin, 1 mM PMSF, and 10 lg/ml leupeptin). Protein
content was determined against a standardized control, using the
Bio-Rad protein assay kit (Bio-Rad Laboratories). A total of 50 lg
of protein was separated by SDS–PAGE and transferred onto nitrocel-
lulose ﬁlter (NCF) paper (Schleicher & Schuell, Inc., Keene, NH).
Non-speciﬁc binding to the NCF paper was minimized with a blocking
buﬀer containing non-fat dried milk (5%) and Tween 20 (0.1%, v/v) in
PBS (PBS/Tween 20). Then, the NCF paper was incubated with pri-
mary antibodies followed by the horseradish peroxidase-conjugated
goat anti-mouse antibody (1:2500 dilution; Boehringer Mannheim
Corp., Indianapolis, IN). Reactive bands were visualized with an en-
hanced chemiluminescence system (Amersham Corp., Arlington
Heights, IL). The intensity of the bands was scanned and quantiﬁed
with NIH image software.2.6. Soft agar colony formation assay
The eﬀects of apigenin on the soft agar colony formation of various
human breast cells were investigated. Brieﬂy, cells (1 · 104) were seeded
in 6-cm culture dish containing 0.35% low-melting agarose over a 0.7%
agarose layer in the presence of varying concentrations of apigenin or
control vehicle and incubated for 3 weeks at 37 C. Colonies were then
stained with p-iodonitrotetrazolium violet (1 mg/ml) and those colonies
larger than 100 lm were counted.3. Results
3.1. Apigenin-induced cytochrome c release and caspase-3
activation
The release of cytochrome c from the mitochondria is the
central gate in turning on apoptosis. This release is regulated
by the interaction of proapoptotic proteins, including Bid,
Bax and Bak, and antiapoptotic proteins, including Bcl-2
and Bcl-XL, as well as a speciﬁc class of inhibitors of apoptosis
proteins, including Akt, survivin, and heat-shock proteins [17].
In our previous report [16], we found that apigenin inhibits
Akt kinase activity in HER2/neu -overexpressing breast cancer
cells. We next tested whether apigenin also induced cyto-
chrome c release. Fig. 1A clearly shows that apigenin led to
the release of cytochrome c into the cytosol in a dose-depen-
dent manner. Subsequent to the release of cytochrome c, casp-
ases play a central role in mediating various apoptotic
responses. To monitor the enzymatic activity of caspases dur-
ing apigenin-induced apoptosis, we used speciﬁc ﬂuorogenic
peptide substrate (Ac-DEVD-AMC) for caspase-3, and found
that apigenin induced caspase-3 activity in a dose- and time-
dependent manner (Fig. 1B). An inhibitor of caspase-3 prote-
ase, Z-DEVD-FMK, inhibited apigenin-stimulated caspase-3
activity (Fig. 1C). Western blotting results also suggest that
apigenin increases caspase-3 levels by increasing the cleavage
of the caspase-3 precursor pro-caspase-3 in a time- and dose-
dependent manner (Fig. 1D). The above results clearly indicate
that caspase-3 protease is activated in response to apoptosis in-
duced by apigenin.3.2. Apigenin treatment causes the cleavage of DFF-45, an
inhibitor of endonuclease
DFF, a DNA fragmentation factor, has been identiﬁed as a
heterodimeric protein that triggers DNA fragmentation during
apoptosis although DFF has no nuclease activity [18]. Casp-
ases activated by apoptotic signals cleave DFF-45 to release
caspase-activated deoxyribonuclease [19,20]. Once caspase-
Fig. 1. Apigenin-induced cytochrome c release, caspase-3 activation and DFF-45 cleavage. (A) MDA-MB-453 cells were incubated with DMSO
(Con) or apigenin (10, 20 and 40 lM) at 37 C for 24 h. Levels of cytochrome c in the mitochondrial (upper panel) and cytosolic (lower panel)
fraction were analyzed by immunoblotting. (B) MDA-MB-453 cells were incubated with apigenin (20 and 40 lM) at 37 C for various times and cell
lysates were analyzed for caspase-3 activity. Columns represent means for three independent experiments and are expressed relatively to 0 h. Bars
represent S.E. (C) MDA-MB-453 cells were pretreated for 1 h with a caspase inhibitor (Z-DEVD-FMK) prior to the addition of 20 or 40 lM
apigenin for 12 h, and cell lysates were analyzed for caspase-3 activity. Columns represent means of three independent experiments and are expressed
relatively to 0 h. Bars represent S.E. (D) MDA-MB-453 cells were incubated with DMSO (Con) or apigenin (20 lM) at 37 C for various times (upper
column) and for 24 h at various doses (lower column). Levels of pro-caspase-3 and actin were analyzed by immunoblotting. (E) MDA-MB-453 cells
incubated with DMSO (Con) or apigenin (40 lM) at 37 C for various times (lower column) and various doses for 48 h (upper column). Levels of
DFF-45 and actin were analyzed by immunoblotting.
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DFF-45. Then, the cleaved DFF-45 can enter the nucleus
where it degrades chromosomal DNA [18]. We further ex-
plored the possibility that activation of caspase-3 may also in-
duce DFF-45 protein degradation. Indeed, treatment of
MDA-MB-453 cell lines with apigenin caused proteolytic
cleavage of DFF-45 in a dose- and time-dependent manner
(Fig. 1E).
3.3. Apigenin alters cell-cycle regulatory proteins in HER2/neu-
overexpressing breast cancer cells
When Akt is active, it phosphorylates an increasing num-
ber of substrates involved in apoptosis, cell cycle regulation,
protein synthesis, and glycogen metabolism [21]. Akt could
potentially regulate cell cycle progression by phosphorylating
and inactivating GSK-3b, thus stabilizing nuclear b-catenin
and increasing cyclin D1 transcription [22]. By inactivatingGSK-3b, Akt represses GSK-3b-mediated phosphorylation
and the proteolytic turnover of cyclin D1, hence increasing
cyclin D1 levels in the nucleus [23]. In addition, Akt may
contribute to the induction of cell cycle progression by regu-
lating the Cdk inhibitor p27. It is known that PI3K-Akt
pathway controls p27 activity and expression through two
diﬀerent pathways: (a) by transcriptional regulation via phos-
phorylating Forkhead transcription factors, it can inhibit
AFX-mediated transcription of p27 [24]; and (b) posttransla-
tionally, by directly phosphorylating p27 protein at Thr157
site [25]. To address whether cyclin D protein levels were
aﬀected by apigenin, a PI3 kinase inhibitor, cyclin D1 and cy-
clin D3 protein levels were determined by immunoblotting.
As shown in Fig. 2A, there was a notable decrease in the
steady-state levels of cyclin D1 and D3 in HER2/neu-over-
expressing MDA-MB-453 breast cancer cells. In addition,
p27 protein levels were also increased (Fig. 2A), while the
Fig. 2. Immunoblot analysis of cyclin D1, cyclin D3 and p27 proteins
after apigenin treatment. (A) MDA-MB-453 cells were treated with the
PI3K inhibitors wortmannin (Wort; 500 nM), or LY294002 (LY; 20
lM) or apigenin (10, 20 and 40 lM) at 37 C for 16 h. Levels of cyclin
D1, cyclin D3, p27, p21, Cdk2, Cdk4 and actin were analyzed by
immunoblotting. (B) HER2/neu-overexpressing breast cancer cell lines
BT-474 and SKBr-3 were treated with the PI3K inhibitors wortmannin
(Wort; 500 nM), or LY294002 (LY; 20 lM) or apigenin (10, 20 and 40
lM) at 37 C for 16 h. Levels of cyclin D1 and p27 were analyzed by
immunoblotting.
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mannin and LY294002 are known to be irreversible PI3K
inhibitors, and were used here as positive controls (Fig. 2).
The HER2/neu-overexpressing breast cancer cell lines were
slightly inﬂuenced at 16 h post-treatment with wortmannin.
Presumably, it is attributable to wortmannin having a rela-
tively short half-life. To further conﬁrm that the depletion
of the cyclin D1 and p27 protein levels by apigenin is a gen-
eral phenomenon, two other breast cancer cell lines that over-
express HER2/neu (BT-474 and SKBr-3; Fig. 2B) were
analyzed and revealed similar results.
Cyclin D1 serves as the regulatory subunit of Cdk4 and con-
tributes to its stability. Next, we assessed the eﬀects of apigenin
on Cdks protein expression. Treatment of MDA-MB-453
HER2/neu-overexpressing breast cancer cells with apigenin re-
sulted in a dose-dependent decrease in protein expression of
Cdk4. Nevertheless, there was no change in the protein expres-
sion of Cdk2 (Fig. 2A).3.4. Eﬀect of apigenin on anchorage-independent growth of
breast cancer cells
Hermanto et al. [26] indicates that those human breast can-
cer cells with overexpression and activation of HER2/neu dis-
play an increased requirement for a signaling pathway
mediated by PI3K-Akt in anchorage-independent growth. To
determine whether apigenin may aﬀect anchorage-independent
growth, an important hallmark of the transformation pheno-
type, we seeded cells into soft agarose in the presence of con-
trol vehicle or varying concentrations of apigenin and
monitored them for colony formation. After the treatment of
apigenin, the colony-forming activity of HER2/neu-over-
expressing breast cancer cells was signiﬁcantly more sup-
pressed than that of non-overexpressing cell lines (Fig. 3).
This ﬁnding implies that HER2/neu is likely to be the primary
target for the reduction of colony formation.3.5. Eﬀect of various ﬂavonoids on HER-2/neu-overexpressing
human breast cancer MDA-MB-453 cells
Flavonoids are naturally occurring plant polyphenols
found in abundance in diets rich in fruit, vegetables and
plant-derived beverages such as tea. Depending on their
structure, some ﬂavonoids inhibit tyrosine kinase and ser-
ine/threonine kinase activities [27]. In order to investigate
the possible relationship between the chemical structure
and the biological activities, we determine the relationship
between chemical structures of apigenin and various ﬂavo-
noids and their inhibitory activities on the protein level of
HER-2/neu in HER-2/neu-overexpressing breast cancer cell
lines. Nineteen ﬂavonoids were selected for this purpose as
shown in Table 1. Flavonoids are classiﬁed into several clas-
ses including ﬂavonols, ﬂavanones, ﬂavanols and ﬂavans,
according to substitute at diﬀerent structural position. We
treated separately the HER2/neu-overexpressing human
breast cancer MDA-MB-453 cells with 40 lM of 19 com-
pounds at 37 C for 24 h in the presence of serum. After
treatment, the HER-2/neu protein was analyzed and revealed
that the HER2/neu protein could be degraded in the pres-
ence of apigenin, luteolin, naringenin, eriodictyol and hes-
peretin, respectively (Fig. 4). This indicated that the
position, number and substitution of the hydroxyl group
of the 2-phenyl group, and the position of B ring were
important for the depletion of HER2/neu protein by
ﬂavonoids.4. Discussion
We have demonstrated that apigenin induces cytochrome c
release and causes a rapid induction of caspase-3 activity and
stimulates proteolytic cleavage of DFF-45 in HER2/neu-over-
expressing breast cancer cells. In addition, apigenin inhibits
colony formation, downregulates cyclin D1, D3 and Cdk4,
and increases p27 protein levels in HER2/neu-overexpressing
breast cancer cells. These results suggest that apigenin potently
suppresses the growth of HER2/neu-overexpressing breast can-
cer cells, thus its therapeutic potential in advanced breast can-
cer is worthy of further investigation.
Many anticancer chemotherapeutic drugs exert their antitu-
mor eﬀect by inducing apoptosis in cancer cells. Resistance to
apoptosis therefore causes a decrease in the sensitivity of can-
Fig. 3. Eﬀect of apigenin on anchorage-independent growth of breast
cancer cells. Cells (1 · 104 cells/well) were seeded onto 6cm dish in
culture medium containing 0.35% low-melting agarose over a 0.7%
agarose layer in the presence of apigenin (10, 20 lM) or vehicle control
(DMSO) and were incubated for 3 weeks at 37 C. Colonies were then
stained with p-iodonitrotetrazolium violet (1 mg/ml) and colonies
larger than 100 lm were counted. (A) A representative size distribution
of BT-474, MDA-MB-453, MCF-7, T47-D and HBL-100 colonies in
the presence of DMSO (Con) (left column) or 10 (middle column) and
20 (right column) lM apigenin. (B) Number of colonies in the presence
of apigenin was expressed as a percentage of the number of colonies in
vehicle control (DMSO). Results from three separate experiments were
averaged and presented as means ± S.E. Students t test was used to
determine the signiﬁcance of inhibition (*P < 0.01; **P < 0.005;
***P < 0.001).
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Activation of proapoptotic genes may be expected to enhance
drug sensitivity in association with apoptosis that is required
for the critical event of cytochrome c release from the mito-
chondria. We show here that treatment of MDA-MB-453 cells
with apigenin induces the release of cytochrome c from mito-
chondria into the cytosol (Fig. 1A) followed by activating cas-pase-3 activities, which are believed to play a central role in
mediating various apoptotic responses (Fig. 1B). These results
corroborate the ﬁndings from published studies [28,29] and
suggest that apigenin may enhance the susceptibility to apop-
tosis in HER2/neu-overexpressing breast cancer cells that are
normally apoptosis-resistant.
By heterodimerization with HER3, HER2/neu can activate
PI3K [30], which phosphorylates membrane phosphoinositides
at the ‘‘3’’ position of the inositol ring. The NH2-terminal
pleckstrin homology domain of Akt binds PI3K-induced
PIP3 in the plasma membrane, in which Akt is activated by
3-phosphoinositide-dependent kinase 1 (PDK1)-mediated
phosphorylation. [31]. Once activated, Akt phosphorylates
an increasing number of substrates involved in apoptosis, cell
cycle regulation, protein synthesis, and glycogen metabolism.
Akt can also phosphorylate and negatively regulate GSK-3b,
thereby inhibiting GSK-3b-mediated phosphorylation of cy-
clin D1 at Thr-286. This phosphorylation accelerates protea-
some-mediated degradation of cyclin D1, thus shortening its
half-life [32]. Therefore, by activating PI3K/Akt and indirectly
disabling GSK-3b, an excess of HER2/neu signals can modu-
late cyclin D1 and p27 and dysregulate the G1-to-S transition.
Similarly, as shown recently that the anti-HER2/neu monoclo-
nal antibody trastuzumab (Herceptin) can reduce cyclin D1
protein levels [33]. In addition, ﬂavopiridol inhibits CDK
activity, lowers cyclin D1 [7], and reduces erbB2 receptor pro-
teins [8]. In our previous study, we proposed that the apigenin-
induced cellular eﬀects resulted from the loss of HER2/neu and
HER3 expression with subsequent inactivation of PI3K and
Akt in cells depending on this pathway for cell proliferation
and inhibition of apoptosis [16]. Here, we demonstrate that
blocking PI3k-Akt pathway can downregulate cyclin D1 and
increase the expression of p27 protein. These results suggest
that HER2/neu may regulate cellular cyclin D1 via PI3k-Akt
pathway, implying that the PI3K-Akt signaling predominantly
contributes to G1-to-S progression.
The marked changes in cyclin D1/Cdk4 levels observed
upon inhibition of HER2/neu support a critical role for this
Cdk4 in HER2/neu-mediated cell cycle progression. Treat-
ment of HER2/neu-overexpressing breast cancer cells with
apigenin and the PI3K inhibitors downregulated Cdk4 pro-
tein, without altered Cdk2 protein (Fig. 2). Interestingly,
our results diﬀerent from recent study have shown a signiﬁ-
cant decrease in protein expression of Cdk2 and Cdk4 in hor-
mone-refractory prostate carcinoma cells [29]. These diﬀerent
results with HER2/neu-overexpressing breast cancer cells and
hormone-refractory prostate carcinoma cells suggest that
unassembled Cdk4 maybe turned over more rapidly and
not accumulate in HER2/neu-overexpressing breast cancer
cells. Whether the reduction of cyclin D1 levels and/or
PI3K activity can contribute to Cdk4 unassembly and desta-
bilization requires further investigation outside the scope of
this report.
The structure of the ﬂavonoids is derived from a heterocyclic
hydrocarbon, chromane, by substitution of its ring C at posi-
tions 2- or 3-with a phenyl-group (ring B) resulting in ﬂavans,
and an oxo-group at the position 4 resulting in ﬂavanones and
isoﬂavanones (see Table 1). Frequently, a double bond (be-
tween C2 and C3 in the ring C) is present providing these com-
pounds with quinone-like properties. Depending on the
substitution in the C-ring, these ﬂavonoids are assigned as ﬂav-
ones (2-phenyl group) or isoﬂavones (3-phenyl group). Recent
Table 1
Chemical structures of the various ﬂavonoids tested for the protein level of HER2/neu in MDA-MB-453 cells
Chemical formula Name Substitution
5 6 7 8 2 0 30 40 50
Flavones
Flavone H H H H H H H H
5-Methoxyﬂavone OCH3 H H H H H H H
7,8-Dihydroxyﬂavone H H OH OH H H H H
Chrysin OH H OH H H H H H
Apigenin OH H OH H H H OH H
Luteolin OH H OH H H OH OH H
Flavonols
Galangin OH H OH H H H H H
Kaempferol OH H OH H H H OH H
Fisetin H H OH H H OH OH H
Quercetin OH H OH H H OH OH H
Myricetin OH H OH H H OH OH OH
Rutin OH H OH H H OH OH H
Flavonol glucoside (3: OR; R: Rhamnosylglucoside)
Flavanones
Pinocembrin OH H OH H H H H H
Naringenin OH H OH H H H OH H
Isosakuranetin OH H OH H H H OCH3 H
Eriodictyol OH H OH H H OH OH H
Hesperetin OH H OH H H OH OCH3 H
Isoﬂavones Genistein OH H OH H H H OH H
Biochanin A OH H OH H H H OCH3 H
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ﬂavonoids may be potent inhibitors of several kinases involved
in signal transduction, mainly protein kinase C [34] and tyro-
sine kinases [35–37]. These studies have shown that the posi-
tion and number of the hydroxyl group on the 2-phenyl ring
strongly inﬂuence the conformation of the molecule and mod-
ulate their inhibitory eﬀect. As shown previously [37], the
introduction of hydroxyl groups on the ﬂavone ring increased
the inhibitory potency of the PI3-kinase of ﬂavonoids, the
polyhydroxylated ﬂavonol, myricetin, being by far the most
eﬀective. The replacement of hydroxyl groups with methoxyl
groups yielded much weaker inhibitors (diosmetin), suggesting
the importance of hydrogen bonds between ﬂavonoids and the
kinase. Genistein, daidzein and genistin induce diﬀerentiation
of mouse erythroleukemia cells (MEL). While biochanin A
and apigenin have no such eﬀect. These results imply that
the ﬂavonoid structure and the 4 0-hydroxyl group on the 3-
phenyl ring are essential for the induction of diﬀerentiation
[38]. We demonstrated previously that the potency of these
ﬂavonoids towards apoptosis was: apigenin > querce-
tin > myricetin > kaempferol in HL-60 cells treated with 60
lM ﬂavonoids. Thus, these ﬁndings oﬀer a possibility that ﬂa-
vonoid-induced caspase-3 activation may be dependent on the
number of hydroxyl groups in the 2-phenyl group and the exis-
tence of the 3-hydroxyl group [28].
In this study, we investigated the inhibitory action of 19
ﬂavonoids of four chemical classes on the degradation of
HER2/neu protein, a receptor which plays an important rolein the development of one-third of human breast cancers.
We treated the HER2/neu-overexpressing human breast cancer
MDA-MB-453 cells with these 19 compounds at 37oC for 24 h.
The results reveal that HER2/neu protein can be degraded by
apigenin, luteolin, naringenin, eriodictyol and hesperetin.
The IC50 of apigenin, luteolin, naringenin, eriodictyol and hes-
peretin inhibited HER2/neu protein expression were
12.12 ± 0.86, 4.57 ± 0.61, 47.89 ± 1.22, 45.95 ± 2.57 and
21.47 ± 1.57 lM, respectively. Interestingly, these ﬂavonoids
belong to ﬂavones and ﬂavanones only, while ﬂavonals and
isoﬂavones do not possess the ability to deplete HER/neu pro-
tein. The result indicates that the phenyl group at position 3 (3-
phenyl group; isoﬂavones) and the hydroxyl group at position
3 do not have the potency to deplete HER2/neu protein under
the concentration used in this study. These results suggest that
the 2-phenyl group is essential for the degradation of HER2/
neu. The introduction of hydroxyl group at position 4 0 of 2-
phenyl group increases the inhibitory potency of ﬂavonoids.
For example, the replacement of hydroxyl group with methox-
yl substituent yields no inhibitory function (isosakuranetin),
suggesting the importance of 4 0-hydroxyl group on the 2-phe-
nyl group. Taken together, the results of this study demon-
strate that the structural features of ﬂavonoids necessary for
depleting HER2/neu protein are (1) the position of B ring;
and (2) the existence of the 3 0, 4 0-hydroxyl group on the 2-phe-
nyl group. These provide new information for the design of
cancer chemopreventive agents and the study of these func-
tional groups in the future.
Fig. 4. Eﬀect of various ﬂavonoids on the expression of HER2/neu
protein. MDA-MB-453 cells were incubated with DMSO (Con) or 1,
ﬂavone; 2, 5-methoxyﬂavone; 3, 7,8-dihydroxyﬂavone; 4, chrysin; 5,
apigenin; 6, luteolin; 7, galangin; 8, kaempferol; 9, ﬁsetin; 10,
quercetin; 11, myricetin; 12, rutin; 13, pinocembrin; 14, naringenin;
15, isosakuranetin; 16, eriodictyol; 17, hesperetin; 18, genistein; 19,
biochanin A (40 lM) at 37 C for 24 h. Immunoblotting was used to
measure protein levels of HER2/neu and actin.
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